Ashwagandha Liver Safety: What the Evidence Shows
Informational summary of published case reports and FDA adverse-event data — not medical advice and not a diagnosis. If you think you may be experiencing liver injury, stop the supplement and see a doctor rather than relying on this page.
Two different data sources say different things here, and both matter. Published case reports describe rare but real ashwagandha-associated liver injury — jaundice, dark urine, itching, fatigue. It usually shows up 2-12 weeks after you start and resolves after you stop. Separately, FDA adverse-event reports on ashwagandha (166 total, 62.7% serious) are dominated by GI and skin reactions like diarrhea, nausea, and itching, not liver-specific ones — and that database can't tell you how likely any reaction is, because it has no denominator. People with liver disease should avoid ashwagandha. In the reported cases, people who developed jaundice, dark urine, or unusual fatigue stopped the supplement and got evaluated by a clinician, and the injury resolved after stopping.
Looking for products, not safety detail? See our best ashwagandha ranked by cost per studied dose, which also covers this caution →
What the published case reports show
The liver-injury signal for ashwagandha comes from clinical case reports, not a randomized trial or a large safety database. Two case series make up the core of the evidence: a 2020 report from the US Drug-Induced Liver Injury Network describing cases in Iceland and the US (Björnsson et al., PMID: 31991029), and a 2023 case series from India (Philips et al., PMID: 37756041). Both describe a cholestatic injury pattern — impaired bile flow, with jaundice and itching as hallmark signs. It typically showed up 2-12 weeks after starting ashwagandha and resolved after stopping, though rare severe cases occurred. The NIH's LiverTox database, which tracks drug- and supplement-induced liver injury, classifies ashwagandha as an uncommon but likely cause of clinically apparent liver injury (LiverTox, NBK548536).
Case reports establish that this injury pattern happens, and roughly what it looks like when it does. They can't tell you how common it is. Case reports are, by definition, a collection of instances that got noticed and published, not a systematic count of everyone who took ashwagandha.
What FDA adverse-event data does — and doesn't — show
The top FAERS reactions for ashwagandha are gastrointestinal and skin-related, not hepatic. FDA adverse-event data (FAERS/CAERS) logs 166 total reports naming ashwagandha. Of those, 104 (62.7%) were coded as serious. But the most-reported reactions are Diarrhoea, Nausea, Pruritus, Headache, Vomiting — diarrhea, nausea, itching, headache, and vomiting dominate, not liver-specific terms. That's an easy-to-miss distinction: FAERS' own top reactions don't surface the liver-injury caution on this page at all. That caution comes from the separate published case reports above.
It's also worth being precise about what a 62.7% "serious" rate does and doesn't mean. FAERS/CAERS is a voluntary, spontaneous reporting system. Anyone — a consumer, a pharmacist, a manufacturer — can file a report, and nothing requires that they do. A report being filed doesn't mean ashwagandha caused the reaction. There's no denominator: no count of how many people took ashwagandha during the same period. That means these numbers can't become an incidence rate, a "your risk is X%" statement, or a comparison of how likely a reaction is versus any other supplement. A few known limits of this data:
- Reports are voluntary — not all adverse events are reported
- No causal proof — a reported event does not mean the supplement caused it
- High-selling products naturally accumulate more reports (volume bias)
- Brand name matching is fuzzy — some reports may be misattributed or missed
FAERS/CAERS figures via the Verified Supplement Evidence Database, source: FDA CAERS (FAERS for Foods/Supplements).
Putting the two sources together
Neither data source alone gives you a complete picture, and neither should be read as if it does. The case reports establish that a rare, specific, cholestatic liver injury pattern shows up in some people who take ashwagandha, with a plausible timeline (2-12 weeks) and a documented reversal pattern that resolves after stopping. The FAERS data shows a real burden of adverse events overall — a majority coded serious. But its most-reported symptoms point toward the gut and skin, not the liver, and it can't tell you how often the liver-specific injury described in the case reports actually happens. Treat the case reports as your source for "this can happen, and here's what it looks like." Treat FAERS as evidence of general reporting volume and severity — not as a liver-specific signal, and not as a rate.
Who should avoid or be cautious
These cautions come from the ashwagandha hub and dosage guide on this site, which draw on NIH's LiverTox and NCCIH resources:
- Existing liver disease: avoid — this is the group the liver-safety signal applies to most directly.
- Pregnancy: avoid — it may cause miscarriage.
- Thyroid conditions: use caution — ashwagandha can raise thyroid hormone levels; talk to your doctor if you have a thyroid condition or take thyroid medication.
- Autoimmune disease: use caution — it may stimulate immune activity.
- Sedatives or immunosuppressants: check with a clinician — effects can be additive.
Warning signs, and what to do
Based on the pattern described in the published case reports, the signs to watch for are:
- Yellowing of the skin or eyes (jaundice)
- Dark urine
- Persistent itching
- Nausea
- Unusual or unexplained fatigue
If you notice any of these while taking ashwagandha, the published case reports and the NIH LiverTox database point the same direction: stopping the supplement and getting evaluated promptly. This page can't tell you whether a symptom is related to ashwagandha or something else — that call needs a clinician, not a website. The case reports do note that the injury pattern generally resolved once people stopped, which is why the reported course is prompt evaluation rather than waiting to see.
The two data sources, side by side
| Signal source | What it shows | What it cannot tell you |
|---|---|---|
| Published case reports (Björnsson 2020, Philips 2023) | Rare cholestatic liver injury, appearing 2–12 weeks after starting, usually resolving after stopping | How common the injury actually is — case reports aren't a systematic count |
| FDA FAERS/CAERS adverse-event data | 166 total reports, 104 serious (62.7%); top reactions are GI/skin (Diarrhoea, Nausea, Pruritus) | An incidence rate or causation — voluntary system, no denominator |
| NIH LiverTox classification | Classifies ashwagandha as an uncommon but likely cause of clinically apparent liver injury | How likely any individual user is to experience it |
Frequently asked questions
Does ashwagandha cause liver damage?
Rarely, but yes — it's documented. Two published case series (Björnsson 2020, PMID 31991029; Philips 2023, PMID 37756041) describe ashwagandha-associated liver injury, typically a cholestatic pattern that showed up 2-12 weeks after starting and resolved after stopping, though rare severe cases occurred. NIH LiverTox classifies ashwagandha as an uncommon but likely cause of clinically apparent liver injury. This is a case-report signal, not something from a large controlled trial, so it can't tell you how common the reaction actually is.
What do FDA adverse-event reports show about ashwagandha safety?
FDA adverse-event data (FAERS/CAERS) on ashwagandha shows 166 total reports, 104 of them serious (62.7%). But the most-reported reactions in that database are gastrointestinal and skin-related — diarrhea, nausea, itching, headache, and vomiting — not liver injury. The liver-injury signal on this page comes from separately published case reports, not from the top of this adverse-event list. FAERS is voluntary and has no denominator, so none of these figures can become an incidence rate or a "how likely" estimate.
What are the warning signs of ashwagandha-related liver injury?
The case reports describe yellowing of the skin or eyes (jaundice), dark urine, itching, nausea, and unusual fatigue — the signs a cholestatic liver injury typically produces. If any of these show up while you're taking ashwagandha, both the published case reports and the NIH LiverTox database describe the same course: stopping the supplement and getting evaluated promptly, rather than waiting to see if it passes. That call belongs to you and a clinician, but the reports agree that waiting isn't the low-risk option.
Who should avoid or be cautious with ashwagandha?
People with existing liver disease should avoid ashwagandha. A few more cautions worth knowing: avoid it in pregnancy, since it carries a possible miscarriage risk, and use caution with a thyroid condition, since it can raise thyroid hormone levels, or with autoimmune disease, since it may stimulate immune activity. If you take sedatives or immunosuppressants, check with a clinician first, since effects can be additive. None of this replaces individualized medical advice.
Related guides
- Ashwagandha Dosage Guide — Full safety section, thyroid and drug-interaction detail
- Best Ashwagandha Overall — Verified picks, ranked by cost per studied dose
- Best Ashwagandha for Anxiety & Stress — Who should not take it for stress
- All Ashwagandha Guides
Sources
- Björnsson HK, Björnsson ES, Avula B, et al. "Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network." Liver Int. 2020;40(4):825-829. PMID: 31991029
- Philips CA, Theruvath AH, Ravindran R, et al. "Ashwagandha-induced liver injury—a case series from India and literature review." Hepatol Commun. 2023;7(1):e0019. PMID: 37756041
- NIH LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — Ashwagandha. NCBI Bookshelf. NBK548536
- NIH National Center for Complementary and Integrative Health (NCCIH). Ashwagandha: Usefulness and Safety. nccih.nih.gov
- NIH Office of Dietary Supplements. "Ashwagandha: Is it helpful for stress, anxiety, or sleep?" ods.od.nih.gov
- FDA CAERS (FAERS for Foods/Supplements) — ashwagandha category summary, via the site's Verified Supplement Evidence Database.